secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2023-12-05T23:59:59+00:00
Accession:  0000950170-23-068277
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema reports positive Phase 1b/2 combo data for palazestrant; Phase 3 OPERA-01 enrolling
--------------------------------------------------------------------------------

- Palazestrant + ribociclib (19 patients) well-tolerated; no dose-limiting toxicities, no drug-drug interaction.
- Palazestrant + palbociclib (46 patients): clinical benefit rate 46% overall, 60% in ESR1 mutant, 71% in CDK4/6-naïve.
- OPERA-01 Phase 3 monotherapy trial initiated; first patient dosed November 2023; sites activated.
- Company anticipates potential Phase 3 combo trial start with ribociclib as early as end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000095017023068277/0000950170-23-068277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000095017023068277/olma-20231205.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-068277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer